Stay updated with breaking news from Dan Budwick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- High neutralizing antibody responses sustained through at least 12 months, highlighting potential for durable clinical protection -- -- T cell responses to Spike plus other viral targets observed...
-- High neutralizing antibody responses sustained through at least 12 months, highlighting potential for durable clinical protection -- -- T cell responses to Spike plus other viral targets observed...
$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash, cash equivalents...
GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study Significant weight loss at 28 days supporting once-daily...
-- 10,000 participant randomized Phase 2b study will evaluate Gritstone’s self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus other viral targets with an approved vaccine against COVID-19 --